Valuation
- Market cap
- 995,000
- Revenue TTM
- $4,000
- Net income TTM
- $-124,120,000
- P/E (trailing)
- 0.00
- P/E (forward)
- —
- Profit margin
- 0.00%
- Debt to equity
- -0.18
Trading
- Volume
- 337,900
- Avg volume
- 166,274
- Day's range
- $0.15 – $0.38
- Shares out
- 4,523,000
- Stochastic %K
- 11%
- Beta
- 1.12
- Analysts
- Strong Buy
- Price target
- $34.00
Company profile
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of l...
Show more
Biora Therapeutics, Inc., a clinical-stage biotechnology company, engages in developing oral biotherapeutics in the United States. The company offers NaviCap, a targeted oral delivery platform for delivery of therapeutics in the gastrointestinal tract to enhance the treatment of inflammatory bowel diseases; and BioJet, a systemic oral delivery platform designs to replace injection with needle-free, oral delivery of large molecules for management of chronic diseases. The company was formerly known as Progenity, Inc. and changed its name to Biora Therapeutics, Inc. in April 2022 to reflect its focus on its therapeutics pipeline. Biora Therapeutics, Inc. was founded in 2010 and is headquartered in San Diego, California. On December 27, 2024, Biora Therapeutics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
- Industry
- Biotechnology
- Sector
- Healthcare
- Phone
- 833 727 2841
- Website
- https://www.bioratherapeutics.com
- Address
- 4330 La Jolla Village Drive, Suite 300, San Diego, United States
Latest news
No headlines yet.
